全文获取类型
收费全文 | 2928篇 |
免费 | 187篇 |
国内免费 | 27篇 |
专业分类
耳鼻咽喉 | 62篇 |
儿科学 | 185篇 |
妇产科学 | 35篇 |
基础医学 | 304篇 |
口腔科学 | 110篇 |
临床医学 | 212篇 |
内科学 | 595篇 |
皮肤病学 | 73篇 |
神经病学 | 225篇 |
特种医学 | 174篇 |
外科学 | 448篇 |
综合类 | 96篇 |
预防医学 | 99篇 |
眼科学 | 97篇 |
药学 | 210篇 |
中国医学 | 14篇 |
肿瘤学 | 203篇 |
出版年
2023年 | 21篇 |
2022年 | 62篇 |
2021年 | 140篇 |
2020年 | 70篇 |
2019年 | 94篇 |
2018年 | 103篇 |
2017年 | 79篇 |
2016年 | 101篇 |
2015年 | 91篇 |
2014年 | 154篇 |
2013年 | 154篇 |
2012年 | 222篇 |
2011年 | 185篇 |
2010年 | 127篇 |
2009年 | 74篇 |
2008年 | 109篇 |
2007年 | 140篇 |
2006年 | 149篇 |
2005年 | 115篇 |
2004年 | 98篇 |
2003年 | 68篇 |
2002年 | 58篇 |
2001年 | 52篇 |
2000年 | 65篇 |
1999年 | 58篇 |
1998年 | 47篇 |
1997年 | 40篇 |
1996年 | 29篇 |
1995年 | 17篇 |
1994年 | 19篇 |
1993年 | 15篇 |
1992年 | 23篇 |
1991年 | 25篇 |
1990年 | 30篇 |
1989年 | 23篇 |
1988年 | 19篇 |
1987年 | 25篇 |
1986年 | 22篇 |
1985年 | 20篇 |
1984年 | 22篇 |
1983年 | 17篇 |
1982年 | 11篇 |
1978年 | 11篇 |
1977年 | 13篇 |
1976年 | 9篇 |
1975年 | 16篇 |
1974年 | 11篇 |
1973年 | 9篇 |
1972年 | 10篇 |
1971年 | 11篇 |
排序方式: 共有3142条查询结果,搜索用时 15 毫秒
51.
52.
53.
Goyal VS Fulwani MC Ramakantan R Kulkarni HL Dalvi BV 《The American journal of cardiology》1999,83(3):463-6, A10
A prospective serial follow-up after coil closure of patent ductus arteriosus in 84 patients showed a cumulative duct closure up to 96% at the end of 2 years. Five patients underwent transient recanalization, and 4 patients required repeat procedure for residual shunt or recanalization. 相似文献
54.
Powles R Sirohi B Kulkarni S Treleaven J Rudin C Sankpal S Goyal S Horton C Millar B Saso R Singhal S Mehta J 《Bone marrow transplantation》2002,30(8):479-484
We have shown that primary therapy with non-myeloablative (140 mg/m(2)) high-dose melphalan (HDM) without hematopoietic support results in high response rates in untreated myeloma and very long-term survival of some patients. This study was designed to see if sufficient CD34 (+) cells can be harvested at presentation in newly diagnosed patients to administer myeloablative HDM (200 mg/m(2); HDM200) with autograft as primary therapy. This may improve outcome by rapid achievement of complete remission (CR) and possible avoidance of late myelodysplasia as a consequence of non-transplant induction chemotherapy. Thirty untreated patients received 1 g/m(2) methylprednisolone daily (days 1-6) and 12-16 micro g/kg G-CSF daily (days 3-6), and underwent leukapheresis on days 6 and 7. The median CD34(+) cell yield was 1.31 x10(6)/kg (range, 0.23-5.63), and was > or =1 x10(6)/kg in 73%. Cell yields were significantly lower than in 82 historical controls apheresed after completion of induction chemotherapy (median 2.16 x 10(6)/kg), and improved in patients who were apheresed again after induction chemotherapy. Three patients received primary therapy with HDM200 and autograft using these cells and attained CR. We conclude that it is possible to harvest stem cells in three-quarters of untreated myeloma patients. Increasing the number of apheresis procedures is needed to improve the number of CD34(+) cells collected. 相似文献
55.
56.
Alkesh Kumar Khurana Vikas Gupta Deepti Joshi Abhishek Goyal Ujjawal Khurana Abhijit Pakhare 《The Indian journal of tuberculosis》2021,68(2):215-220
IntroductionThe variable course of illness in patients of Tubercular lymphadenitis remains a therapeutic challenge to treating physicians in a significant proportion of patients. This study was aimed to explore the possible determinants which could predict the outcome of this subgroup of patients.MethodologyThis was a prospective cohort study where 94 patients of TB lymphadenitis were enrolled who could be followed up till the end of treatment. They were evaluated in the beginning and monitored till the end of treatment keeping into account the clinical behaviour of lymph nodes during the course of Anti tubercular chemotherapy.ResultsOut of 94 patients, 60 had their lymph nodes resolved at the end of prescribed treatment duration wheras 34 were classified as partial responders. Another 26 amongst them had their nodes resolved by an extension of continuation phase by 3–6 months. Presence of bilateral and multiple lymph nodes, necrosis on Fine needle aspiration at initial diagnosis and occurrence of Paradoxical upgrading reaction were associated with the partial resolution of lymph nodes at the end of stipulated ATT duration.ConclusionTreatment duration should be individualized by the treating physicians. Certain parameters mentioned above can be taken as warning signals of patients ending up as partial responders and hence the need of a prolonged extension phase. 相似文献
57.
Background: Conventional oral dosage forms exhibit poor/low bioavailability due to incomplete release of drug and short residence time at the absorption site. Gastro-retentive drug delivery system (GRDDS) is particularly used to improve bioavailability of the drugs, which have narrow absorption window down in the levels of gastrointestinal tract and also to treat local disorders.Purpose: The purpose of this review is to describe the utility of the nanofibers as gastro-retentive dosage form. From last few decades, formulation scientists have put extensive efforts to develop suitable gastro-retentive drug delivery system, which is appropriate for commercialization. Current approaches used for preparation of gastro-retentive drug delivery system offers limited functional features to control the floating behavior. Recently, an extensive research has been developed to improve the gastric residence time by using nanofibers, which ultimately leads to the increased bioavailability of the drug. Multiple functional features and unique properties of nanofibers improve its gastro retention.Conclusion: Nanofiber system provides stomach-specific drug release for longer duration; moreover, increased local action of the drug due to prolonged contact time with the gastric mucosa. Thus, the nanofiber system promises to be the potential approach for gastric retention drug delivery system. 相似文献
58.
59.
Acute graft‐versus‐host disease (GVHD) is a common and serious complication of allogeneic blood and marrow transplantation. Acute GVHD is commonly graded according to modified Glucksberg criteria. There is considerable within‐grade heterogeneity with different patterns of skin, liver, or gut involvement. In this commentary, we provide an analytical review of ambiguities in acute GVHD severity scoring and offer specific proposals meant to generate discussion in the BMT community for adoption, refinement, and where appropriate, validation studies. 相似文献
60.
High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy 总被引:2,自引:1,他引:2
Brown RA; Herzig RH; Wolff SN; Frei-Lahr D; Pineiro L; Bolwell BJ; Lowder JN; Harden EA; Hande KR; Herzig GP 《Blood》1990,76(3):473-479
Seventy-five patients with resistant acute leukemia or lymphoma received high-dose cyclophosphamide and etoposide to explore the activity of this combination in resistant hematologic malignancies, and to determine the maximum doses of these drugs that can be combined without bone marrow transplantation. Etoposide was administered over 29 to 69 hours by continuous infusion corresponding to total doses of 1.8 g/m2 to 4.8 g/m2. Cyclophosphamide, 50 mg/kg/d, was administered on 3 or 4 consecutive days total 150 to 200 mg/kg ideal body weight). At all dose levels myelosuppression was severe but reversible. Mucosal toxicity was dose-limiting with the maximum tolerated dose level combining etoposide 4.2 g/m2 with cyclophosphamide 200 mg/kg. Continuous etoposide infusion produced stable plasma levels that were lower than would be achieved after administration by short intravenous infusion, and this could explain our ability to escalate etoposide above the previously reported maximum tolerated dose. There were 28 complete (35%) and 12 partial (16%) responses. Median duration of complete response (CR) was 3.5 months (range 1.1 to 20+). Seventeen of 40 patients (42%) with acute myelogenous leukemia (AML) achieved CR, including 6 of 20 (30%) with high-dose cytosine arabinoside resistance. We conclude that bone marrow transplantation is not required after maximum tolerated doses of etoposide and cyclophosphamide. This regimen is active in resistant hematologic neoplasms, and the occurrence of CR in patients with high-dose cytosine arabinoside-resistant AML indicates a lack of complete cross-resistance between these regimens. 相似文献